Laboratory Employees Anonymously Select BioReference amongst 500 Other Large Companies ELMWOOD PARK, NJ, April 17, 2019 (GLOBE NEWSWIRE) — BioReference Laboratories, Inc., an OPKO Health Company (NYSE:OPK), is pleased to announce it has been recognized by Forbes as one of America’s Best Large Employers of 2019. This list includes 500 large companies, and BioReference is one […]
Category Archives: Press Release
ELMWOOD PARK, Jan. 28, 2019 – BioReference Laboratories Inc., an OPKO Health Company, today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown. “We recognize the challenging financial position that federal government employees have faced throughout the shutdown,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “While the […]
Geoff Monk promoted to President MIAMI, Jan. 07, 2019 – OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Jon R. Cohen, M.D. as Executive Chairman of BioReference Laboratories. BioReference, with its GeneDx unit, is the third largest clinical laboratory in the United States. OPKO also announced the promotion of Geoff Monk to President of BioReference. Mr. Monk joined BioReference as General […]
MIAMI, FL NOVEMBER 8, 2018 — BioReference Laboratories, Inc. (BRL), an OPKO Health company and the third largest clinical laboratory in the United States, will remain an in-network provider with Horizon Health Services, Inc. (Horizon), New Jersey’s oldest and largest health insurer. After an extensive evaluation of its laboratory network, BRL will remain a preferred laboratory in the Horizon PPO network. The […]
MIAMI, May 18, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc.(Nasdaq:OPK) today announced that Novitas Solutions, Inc. issued a draft local coverage determination (LCD) for the 4Kscore test®. The draft LCD is a proposed non-coverage policy for the 4Kscore test for Medicare and, prior to its effectiveness, is subject to a public comment period ending July 5, 2018. OPKO plans to submit comments during […]
MIAMI, May 01, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK) today announced the appointment of Geoff Monkas General Manager with overall responsibility for BioReference Laboratories (BRL), an OPKO Health company and the third largest clinical laboratory in the United States. Mr. Monk brings to BRL more than 20 years of operational, business strategy and technical experience. Previously, Mr. Monk worked as Managing Director of […]
Study of 11,506 men shows that healthy men with an abnormal PSA and a low 4Kscore test result can be safely monitored rather than undergo prostate biopsy MIAMI, March 16, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK) today announced that data from a landmark study of the 4Kscore® test entitled, “Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel […]
MIAMI, Jan. 26, 2018 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK), announces that Gregory Henderson, M.D., Ph.D., has resigned from his position as President of BioReference Laboratories, an OPKO Health company and the third largest commercial laboratory in the United States, effective immediately. The Company has begun a search for his replacement and, in the interim, a committee of senior management will assume operational […]
MIAMI and ORLANDO, Fla., Sept. 19, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK) (“OPKO” or “the Company”), announces that BioReference Laboratories, an OPKO Health company and one of the largest commercial laboratories in the U.S., has formed a national affiliation with The Garage, a dynamic, healthcare technology change agent, to provide clinicians with advanced tools to guide quality, value-based care. BioReference Laboratories is led by pathologists […]
MIAMI, May 18, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability to accurately predict aggressive prostate cancer were presented in a podium presentation on May 16, 2017 at the 112thAmerican Urological Association (AUA) Annual Meeting in Boston. The study entitled, “An Independent, Multi-Institutional, Prospective […]
